|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Imatinib-induced fatal acute liver failure显示文摘Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia (CML) in blast crisis, accelerated or chronic phase, and also for advanced gastrointestinal stromal tumors. Severe hepatic toxicity and three deaths from hepatic failure have been reported. We report the case of a 51-year-old woman who was admitted to our institution with severe acute hepatitis. She was diagnosed with CML and began treatment with imatinib mesylate at a dose of 400 mg/d. Five months after beginning treatment, she developed severe hepatitis associated with coagulopathy, and was admitted to our institution. She had been consuming acetaminophen 500-1000 mg/d after the onset of symptoms. She had a progressive increase in bilirubin level and a marked decrease of clotting factor Ⅴ. Five days after admission, grade Ⅱ encephalopathy developed and she was referred for liver transplantation. Her clinical condition progressively deteriorated, and 48 h after being referred for transplantation she suffered a cardiac arrest and died. This report adds concern about the possibility of imatinib-mesylate-induced hepatotoxicity and liver failure, particularly in the case of concomitant use with acetaminophen. Liver function tests should be carefully monitored during treatment and, with the appearance of any elevation of liver function tests, treatment should be discontinued. | Ezequiel Ridruejo Roberto Cacchione Alejandra G Villamil Sebastián Marciano Adrián C Gadano Oscar G Mandó | 2007 | World Journal of Gastroenterology2007，13，48： | 5 |
| 2 | Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir显示文摘Results from phaseⅢclinical trials clearly demonstrate the efficacy and safety of entecavir and tenofovir in the controlled environment of randomized clinical studies.There are several studies with both drugs performed in clinical practice(also called'real life studies').Despite the pros and cons,studies performed in real life conditions represent everyday practice and add important information about long term treatment effectiveness and safety in this clinical setting.This review shows that patients treated with first line nucleos(t)ide analogs at referral centres,with good clinical follow-up and adherence to international guidelines,can achieve high treatment response rates with a very low rate of adverse events. | Ezequiel Ridruejo | 2014 | World Journal of Gastroenterology2014，20，23： | 4 |
| 3 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 4 | Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges显示文摘Latin America, a region with a population greater than 600000000 individuals, is well known due to its wide geographic, socio-cultural and economic heterogeneity. Access to health care remains as the main barrier that challenges routine screening, early diagnosis and proper treatment of hepatocellular carcinoma(HCC). Therefore, identification of population at risk, implementation of surveillance programs and access to curative treatments has been poorly obtained in the region. Different retrospective cohort studies from the region have shown flaws in the implementation process of routine surveillance and early HCC diagnosis. Furthermore, adherence to clinical practice guidelines recommendations assessed in two studies from Brazil and Argentina demonstrated that there is also room for improvement in this field, similarly than the one observed in Europe and the United States. In summary, Latin America shares difficulties in HCC decision-making processes similar to those from developed countries. However, a transversal limitation in the region is the poor access to health care with the consequent limitation to standard treatments for overall population. Specifically, universal health care access to the different World Health Organization levels is crucial, including improvement in research, education and continuous medical training in order to expand knowledge and generation of data promoting a continuous improvement in the care of HCC patients. | Federico Pinro Jaime Poniachik Ezequiel Ridruejo Marcelo Silva | 2018 | World Journal of Gastroenterology2018，24，37： | 4 |
| 5 | Intermediate-advanced hepatocellular carcinoma in Argentina:Treatment and survival analysis显示文摘BACKGROUND Hepatocellular carcinoma(HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.AIM To describe real-life treatments performed in patients with intermediateadvanced HCC before the approval of new systemic options.METHODS This longitudinal observational cohort study was conducted between 2009 and2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer(BCLC) HCC stages(BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death.Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios(HR) calculations and 95% confidence intervals(95%CI).RESULTS From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D.Corresponding median survival were 15 mo(IQR 5-26 mo), 5 mo(IQR 2-13 mo)and 3 mo(IQR 1-13 mo)(P < 0.0001), respectively. Among BCLC-B patients(n =135), 57% received TACE with a median number of 2 sessions(IQR 1-3 sessions).Survival was significantly better in BCLC-B patients treated with TACE HR =0.29(CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival (HR = 0.15(CI: 0.04-0.56, P = 0.005))Eighty-two patients were treated with sorafenib, mostly BCLC-B and C(87.8%). However,12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo(IQR 2.3-11.7 mo);which was lower among BCLC-D patients 3.2 mo(IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients,treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26(CI: 0.09-0.71);P= 0.013].CONCLUSION In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC. | Federico Pinero Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Gustavo Romero Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2019 | World Journal of Gastroenterology2019，25，27： | 3 |
| 6 | Safety of long-term nucleos(t)ide treatment in chronic hepatitis B显示文摘 | Ezequiel Ridruejo Marcelo O Silva | 2012 | Expert Opinion on Drug Safety2012，，3： | 2 |
| 7 | Relapse rates in chronic hepatitis B na?ve patients after discontinuation of antiviral therapy with entecavir显示文摘 | E. Ridruejo S. Marciano O. Galdame M. V. Reggiardo A. E. Mu?oz R. Adrover D. Cocozzella N. Fernandez C. Estepo M. Mendizábal G. A. Romero D. Levi T. Schroder S. Paz H. Fainboim O. G. Mandó A. C. Gadano M. O. Silva | 2014 | J Viral Hepat2014，，8： | 1 |
| 8 | Safety of long-term nucleos(t)ide treatment in chronic hepatitis B显示文摘 | RIDRUEJO E SILVA M O | 2012 | Expert Opin Drug Saf2012，11，3： | 1 |
| 9 | Safety of direct -acting antivirals in the treat- ment of chronic hepatitis C显示文摘 | RIDRUEJO E | 2014 | Expert Opin Drug Saf2014，13，3： | 1 |
| 10 | A constitutive modelfor the in-plane mechanical behavior of nonwoven fabrics 显示文摘 | RIDRUEJO A GONZALEZ C LLORCA J | 2012 | Inter-national Journal of Solids and Structures2012，49，17： | 1 |
| 11 | Efficacy and safety of long term entecavir in chronic hepatitis B treatment naive patients in clinical practice显示文摘 | Ridruejo E Marciano S Galdame O | 2014 | Ann Hepatol2014，13，3： | 1 |
| 12 | Safety of long-term nucleos(t)- ide treatment in chl'onic hepatitis B 显示文摘 | RIDRUEJO E SILVA M O | 2012 | Expert Opin Drug Saf2012，11，3： | 1 |
| 13 | A constitutive model for the in-plane mechanical behavior of nonwoven fabrics显示文摘 | RIDRUEJO A C GONZALEZ J LLORC A | 2012 | International Journal of Solids and Structures2012，49，17： | 1 |
| 14 | Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin显示文摘 | Ridruejo E Christensen AF Mando OG | 2006 | Eur J Gastroenterol Hepatol2006，18，6： | 1 |
| 15 | A constitutive model for the in-plane mechanical behavior of nonwoven fabrics 显示文摘 | RIDRUEJO A GONZALEZ C LLORCA J | 2012 | International Journal of Solids and Structures2012，49，17： | 1 |
| 16 | Interconnection network simulation using traces of MPI applications 显示文摘 | Miguel-Alonso J Navaridas J Ridruejo F J | 2009 | In- ternational Journal of Parallel Programming2009，37，2： | 1 |
| 17 | Chylous ascites as the main manifestation of left ventricular dysfunction : a case report 显示文摘 | Ridruejo E Mando OG | 2005 | BMC Gastroenterol2005，5，： | 1 |
| 18 | Efficacy and safety of long term entecavir in chronic hepatitis B treatment na ve patients in clinical practice显示文摘 | Ridruejo E Marciano S Galdame O | 2014 | Ann Hepatol2014，13，3： | 1 |
| 19 | Severe cholestatic hepatitis as the first symptom of secondary syphilis显示文摘 | Ridruejo E Mordoh A Herrera F | 2004 | Dig Dis Sci2004，499，： | 1 |
| 20 | Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t) ide analogues in clinical practice 显示文摘 | Ridruejo E Adrover R Silva MO | 2011 | Hepatology2011，54，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员